Announcement
12 May 2025
In May 2025, the US Administration issued an Executive Order directing federal agencies to ensure that American patients pay no more than the lowest price charged for prescription drugs in other developed nations.
Source
Sign in to access
Number of interventions
1
0 certainly harmful
1 likely harmful
0 liberalising
List of interventions
Related State Acts
Announced: 31 Aug 2026
United States of America: Agreement with Sun Pharma on most-favoured-nation drug pricing and tariff deferral
Announced: 31 Aug 2026
United States of America: Agreement with UCB on most-favoured-nation drug pricing and tariff exemption
Announced: 31 Aug 2026
United States of America: Agreement with Kyowa Kirin on most-favoured-nation drug pricing and tariff deferral
Announced: 31 Aug 2026
United States of America: Agreements with CSL on most-favoured-nation drug pricing and onshoring
Announced: 31 Aug 2026
United States of America: Agreement with BeOne Medicines on most-favoured-nation drug pricing and tariff exemption
Announced: 18 Jun 2026
United States of America: Initiation of Section 301 investigation into Germany's pharmaceutical pricing
Clarification: 30 Oct 2026
United States of America: Agreement with Regeneron on Most-Favoured-Nation drug pricing and tariff exemption
Announced: 12 Jan 2026
United States of America: Agreement with AbbVie on Most-Favoured-Nation drug pricing and tariff exemption
Announced: 08 Jan 2026
United States of America: Agreement with Johnson & Johnson on Most-Favoured-Nation drug pricing and tariff exemption
Announced: 19 Dec 2025
United States of America: Agreement with Amgen on Most-Favoured-Nation drug pricing and tariff exemption
Announced: 19 Dec 2025
United States of America: Agreement with Boehringer Ingelheim on Most-Favoured-Nation drug pricing and tariff exemption
Announced: 19 Dec 2025
United States of America: Agreement with Bristol Myers Squibb on Most-Favoured-Nation drug pricing and tariff exemption
Announced: 19 Dec 2025
United States of America: Agreement with Genentech on Most-Favoured-Nation drug pricing and tariff exemption
Announced: 19 Dec 2025
United States of America: Agreement with Gilead on Most-Favoured-Nation drug pricing and tariff exemption
Clarification: 08 Sep 2026
United States of America: Agreement with GSK on Most-Favoured-Nation drug pricing and tariff exemption
Announced: 19 Dec 2025
United States of America: Agreement with Merck on Most-Favoured-Nation drug pricing and tariff exemption
Announced: 19 Dec 2025
United States of America: Agreement with Novartis on Most-Favoured-Nation drug pricing and tariff exemption
Implemented: 02 Apr 2026
United States of America: Agreement with Sanofi on Most-Favoured-Nation drug pricing and tariff exemption
Clarification: 28 Sep 2026
United States of America: U.S. Administration imposes Section 232 tariffs on pharmaceutical imports
Threads
See all
United States: Drug Pricing Agreements
This Thread tracks the U.S. Administration’s agreements with pharmaceutical companies. It is based on the Executive Order titled “Delivering Most-Favored-Nation (MFN) Prescription Drug Pricing to American Patients.” These agreements include tariff relief measures for pharmaceutical companies in return for their commitments to implement most-favored-nation pricing for their drugs and to invest i...
Published: 11 Nov 2025
93
interventions
2
jurisdictions
Harmful Trade Policy Measures
This Thread tracks harmful trade policy interventions affecting all products. Covering all types of interventions monitored by Global Trade Alert, it highlights how the yearly number of these measures has evolved over time.
Published: 04 Sep 2024
73860
interventions
193
jurisdictions